145 related articles for article (PubMed ID: 22861193)
1. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
Hu Q; Yin L; Hartmann RW
J Med Chem; 2012 Aug; 55(16):7080-9. PubMed ID: 22861193
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
[TBL] [Abstract][Full Text] [Related]
3. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Barassin C; Marchais-Oberwinkler S; Hartmann RW
J Med Chem; 2005 Oct; 48(21):6632-42. PubMed ID: 16220979
[TBL] [Abstract][Full Text] [Related]
4. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
[TBL] [Abstract][Full Text] [Related]
5. Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
Pinto-Bazurco Mendieta MA; Hu Q; Engel M; Hartmann RW
J Med Chem; 2013 Aug; 56(15):6101-7. PubMed ID: 23859149
[TBL] [Abstract][Full Text] [Related]
6. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
Yin L; Lucas S; Maurer F; Kazmaier U; Hu Q; Hartmann RW
J Med Chem; 2012 Jul; 55(14):6629-33. PubMed ID: 22788843
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
Yin L; Hu Q; Hartmann RW
J Med Chem; 2013 Jan; 56(2):460-70. PubMed ID: 23281812
[TBL] [Abstract][Full Text] [Related]
8. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
[TBL] [Abstract][Full Text] [Related]
10. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
[TBL] [Abstract][Full Text] [Related]
11. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.
Hu Q; Yin L; Ali A; Cooke AJ; Bennett J; Ratcliffe P; Lo MM; Metzger E; Hoyt S; Hartmann RW
J Med Chem; 2015 Mar; 58(5):2530-7. PubMed ID: 25711516
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.
Gobbi S; Hu Q; Negri M; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
J Med Chem; 2013 Feb; 56(4):1723-9. PubMed ID: 23363058
[TBL] [Abstract][Full Text] [Related]
13. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
Müller-Vieira U; Angotti M; Hartmann RW
J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
[TBL] [Abstract][Full Text] [Related]
14. Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis.
Gobbi S; Hu Q; Zimmer C; Engel M; Belluti F; Rampa A; Hartmann RW; Bisi A
J Med Chem; 2016 Mar; 59(6):2468-77. PubMed ID: 26938274
[TBL] [Abstract][Full Text] [Related]
15. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
[TBL] [Abstract][Full Text] [Related]
16. Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
Zhu W; Hu Q; Hanke N; van Koppen CJ; Hartmann RW
J Med Chem; 2014 Sep; 57(18):7811-7. PubMed ID: 25176013
[TBL] [Abstract][Full Text] [Related]
17. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
[TBL] [Abstract][Full Text] [Related]
18. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
Gobbi S; Hu Q; Foschi G; Catanzaro E; Belluti F; Rampa A; Fimognari C; Hartmann RW; Bisi A
Bioorg Chem; 2019 May; 86():401-409. PubMed ID: 30769265
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
Stefanachi A; Hanke N; Pisani L; Leonetti F; Nicolotti O; Catto M; Cellamare S; Hartmann RW; Carotti A
Eur J Med Chem; 2015 Jan; 89():106-14. PubMed ID: 25462231
[TBL] [Abstract][Full Text] [Related]
20. Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.
Hoyt SB; Taylor J; London C; Ali A; Ujjainwalla F; Tata J; Struthers M; Cully D; Wisniewski T; Ren N; Bopp C; Sok A; Verras A; McMasters D; Chen Q; Tung E; Tang W; Salituro G; Clemas J; Zhou G; MacNeil D; Duffy R; Xiong Y
Bioorg Med Chem Lett; 2017 Jun; 27(11):2384-2388. PubMed ID: 28416132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
